In particular, PTEN-negative breast cancers and cells with reduced PTEN expression exhibited increased sensitivity to the anti-proliferative effects of the pan-PI3K inhibitor LY294002 [49]; however, this drug has no clinical application due to its dose limiting toxicity. This evidence concerns the gene PIK3CA and breast cancer.